



## Clinical trial results:

### A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Hospitalized Adults with COVID-19

#### Summary

|                          |                |
|--------------------------|----------------|
| EudraCT number           | 2020-003367-26 |
| Trial protocol           | FR GB SE PL IT |
| Global end of trial date | 11 August 2021 |

#### Results information

|                                |                  |
|--------------------------------|------------------|
| Result version number          | v2 (current)     |
| This version publication date  | 16 December 2022 |
| First version publication date | 10 August 2022   |
| Version creation reason        |                  |

#### Trial information

##### Trial identification

|                       |             |
|-----------------------|-------------|
| Sponsor protocol code | MK-4482-001 |
|-----------------------|-------------|

##### Additional study identifiers

|                                    |   |
|------------------------------------|---|
| ISRCTN number                      | -   |
| ClinicalTrials.gov id (NCT number) | NCT04575584                                   |
| WHO universal trial number (UTN)   | -   |
| Other trial identifiers            | PHRR: PHRR201210-003189, jRCT: jRCT2031200404 |

Notes:

##### Sponsors

|                              |  |
|------------------------------|--|
| Sponsor organisation name    | Merck Sharp & Dohme LLC  |
| Sponsor organisation address | 126 East Lincoln Avenue, P.O. Box 2000, Rahway, NJ, United States, 07065                   |
| Public contact               | Clinical Trials Disclosure, Merck Sharp & Dohme LLC,<br>ClinicalTrialsDisclosure@merck.com |
| Scientific contact           | Clinical Trials Disclosure, Merck Sharp & Dohme LLC,<br>ClinicalTrialsDisclosure@merck.com |

Notes:

##### Paediatric regulatory details

|  |    |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|  |                |
|--|----------------|
| Analysis stage                                       | Final          |
| Date of interim/final analysis                       | 11 August 2021 |
| Is this the analysis of the primary completion data? | Yes            |
| Primary completion date                              | 11 August 2021 |
| Global end of trial reached?                         | Yes            |
| Global end of trial date                             | 11 August 2021 |
| Was the trial ended prematurely?                     | Yes            |

Notes:

## General information about the trial

Main objective of the trial:

This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the rate of sustained recovery through Day 29.

This study was intended to include two parts: Part 1 was a dose-ranging phase 2 study, and Part 2 was a phase 3 study to evaluate the dose selected in Part 1. However, this study was terminated due to business reasons prior to conducting Part 2. Participants in Part 1 were followed until Month 7.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

|   |                 |
|---|-----------------|
| Actual start date of recruitment                          | 19 October 2020 |
| Long term follow-up planned                               | No              |
| Independent data monitoring committee (IDMC) involvement? | Yes             |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                        |
|--------------------------------------|------------------------|
| Country: Number of subjects enrolled | Brazil: 32             |
| Country: Number of subjects enrolled | Chile: 8               |
| Country: Number of subjects enrolled | Colombia: 23           |
| Country: Number of subjects enrolled | France: 15             |
| Country: Number of subjects enrolled | Israel: 15             |
| Country: Number of subjects enrolled | Korea, Republic of: 12 |
| Country: Number of subjects enrolled | Mexico: 23             |
| Country: Number of subjects enrolled | Philippines: 1         |
| Country: Number of subjects enrolled | Poland: 6              |
| Country: Number of subjects enrolled | Russian Federation: 42 |
| Country: Number of subjects enrolled | South Africa: 1        |
| Country: Number of subjects enrolled | Ukraine: 25            |
| Country: Number of subjects enrolled | United Kingdom: 21     |
| Country: Number of subjects enrolled | United States: 46      |
| Country: Number of subjects enrolled | Spain: 34              |

|                                    |     |
|------------------------------------|-----|
| Worldwide total number of subjects | 304 |
| EEA total number of subjects       | 55  |

Notes:

| <b>Subjects enrolled per age group</b>    |     |
|---|-----|
| In utero                                  | 0   |
| Preterm newborn - gestational age < 37 wk | 0   |
| Newborns (0-27 days)                      | 0   |
| Infants and toddlers (28 days-23 months)  | 0   |
| Children (2-11 years)                     | 0   |
| Adolescents (12-17 years)                 | 0   |
| Adults (18-64 years)                      | 205 |
| From 65 to 84 years                       | 93  |
| 85 years and over                         | 6   |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Participants were enrolled at 86 study centers in 15 countries.

### Period 1

|                              |                                |
|------------------------------|--------------------------------|
| Period 1 title               | Overall Study (overall period) |
| Is this the baseline period? | Yes                            |
| Allocation method            | Randomised - controlled        |
| Blinding used                | Double blind                   |
| Roles blinded                | Subject, Investigator          |

### Arms

|                              |     |
|------------------------------|-----|
| Are arms mutually exclusive? | Yes |
|------------------------------|-----|

|                  |                             |
|------------------|-----------------------------|
| <b>Arm title</b> | Part 1: Molnupiravir 200 mg |
|------------------|-----------------------------|

Arm description:

200 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)

|  |              |
|--|--------------|
| Arm type                               | Experimental |
| Investigational medicinal product name | Molnupiravir |
| Investigational medicinal product code |              |
| Other name                             | MK-4482      |
| Pharmaceutical forms                   | Capsule      |
| Routes of administration               | Oral use     |

Dosage and administration details:

Molnupiravir capsule taken by mouth every 12 hours for 5 days

|                  |                             |
|------------------|-----------------------------|
| <b>Arm title</b> | Part 1: Molnupiravir 400 mg |
|------------------|-----------------------------|

Arm description:

400 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)

|  |              |
|--|--------------|
| Arm type                               | Experimental |
| Investigational medicinal product name | Molnupiravir |
| Investigational medicinal product code |              |
| Other name                             | MK-4482      |
| Pharmaceutical forms                   | Capsule      |
| Routes of administration               | Oral use     |

Dosage and administration details:

Molnupiravir capsule taken by mouth every 12 hours for 5 days

|                  |                             |
|------------------|-----------------------------|
| <b>Arm title</b> | Part 1: Molnupiravir 800 mg |
|------------------|-----------------------------|

Arm description:

800 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)

|  |              |
|--|--------------|
| Arm type                               | Experimental |
| Investigational medicinal product name | Molnupiravir |
| Investigational medicinal product code |              |
| Other name                             | MK-4482      |
| Pharmaceutical forms                   | Capsule      |
| Routes of administration               | Oral use     |

Dosage and administration details:

Molnupiravir capsule taken by mouth every 12 hours for 5 days

|  |                 |
|--|-----------------|
| <b>Arm title</b>   | Part 1: Placebo |
| Arm description:<br>Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total) |                 |
| Arm type   | Placebo         |
| Investigational medicinal product name   | Placebo         |
| Investigational medicinal product code   |                 |
| Other name   |                 |
| Pharmaceutical forms   | Capsule         |
| Routes of administration   | Oral use        |

Dosage and administration details:

Placebo capsule matched to molnupiravir taken by mouth every 12 hours for 5 days

| <b>Number of subjects in period 1</b> | Part 1: Molnupiravir<br>200 mg | Part 1: Molnupiravir<br>400 mg | Part 1: Molnupiravir<br>800 mg |
|---------------------------------------|--------------------------------|--------------------------------|--------------------------------|
| Started                               | 75                             | 75                             | 76                             |
| Treated                               | 73                             | 73                             | 72                             |
| Completed                             | 61                             | 60                             | 63                             |
| Not completed                         | 14                             | 15                             | 13                             |
| Not recorded                          | -                              | -                              | -                              |
| Consent withdrawn by subject          | 7                              | 9                              | 5                              |
| Physician decision                    | -                              | 1                              | 1                              |
| Death                                 | 6                              | 4                              | 6                              |
| Lost to follow-up                     | 1                              | 1                              | 1                              |

| <b>Number of subjects in period 1</b> | Part 1: Placebo |
|---------------------------------------|-----------------|
| Started                               | 78              |
| Treated                               | 75              |
| Completed                             | 70              |
| Not completed                         | 8               |
| Not recorded                          | 1               |
| Consent withdrawn by subject          | 3               |
| Physician decision                    | 1               |
| Death                                 | 2               |
| Lost to follow-up                     | 1               |

## Baseline characteristics

### Reporting groups

|  |                             |
|--|-----------------------------|
| Reporting group title  | Part 1: Molnupiravir 200 mg |
| Reporting group description:<br>200 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)           |                             |
| Reporting group title  | Part 1: Molnupiravir 400 mg |
| Reporting group description:<br>400 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)           |                             |
| Reporting group title  | Part 1: Molnupiravir 800 mg |
| Reporting group description:<br>800 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)           |                             |
| Reporting group title  | Part 1: Placebo             |
| Reporting group description:<br>Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total) |                             |

| Reporting group values                       | Part 1: Molnupiravir<br>200 mg | Part 1: Molnupiravir<br>400 mg | Part 1: Molnupiravir<br>800 mg |
|--|--------------------------------|--------------------------------|--------------------------------|
| Number of subjects                           | 75                             | 75                             | 76                             |
| Age categorical<br>Units: participants       |                                |                                |                                |
| Adults (18-64 years)                         | 51                             | 50                             | 53                             |
| From 65-84 years                             | 22                             | 23                             | 23                             |
| 85 years and over                            | 2                              | 2                              | 0                              |
| Age Continuous<br>Units: years               |                                |                                |                                |
| arithmetic mean                              | 56.9                           | 57.0                           | 56.8                           |
| standard deviation                           | ± 14.2                         | ± 14.0                         | ± 13.7                         |
| Sex: Female, Male<br>Units: participants     |                                |                                |                                |
| Female                                       | 32                             | 34                             | 32                             |
| Male   | 43                             | 41                             | 44                             |
| Race (NIH/OMB)<br>Units: Subjects            |                                |                                |                                |
| American Indian or Alaska Native             | 0                              | 3                              | 1                              |
| Asian  | 10                             | 8                              | 4                              |
| Native Hawaiian or Other Pacific<br>Islander | 0                              | 0                              | 1                              |
| Black or African American                    | 1                              | 4                              | 6                              |
| White  | 58                             | 52                             | 54                             |
| More than one race                           | 6                              | 7                              | 9                              |
| Unknown or Not Reported                      | 0                              | 1                              | 1                              |
| Ethnicity (NIH/OMB)<br>Units: Subjects       |                                |                                |                                |
| Hispanic or Latino                           | 27                             | 32                             | 28                             |
| Not Hispanic or Latino                       | 47                             | 42                             | 46                             |
| Unknown or Not Reported                      | 1                              | 1                              | 2                              |

| Reporting group values | Part 1: Placebo | Total |  |
|------------------------|-----------------|-------|--|
| Number of subjects     | 78              | 304   |  |

|   |        |     |  |
|---|--------|-----|--|
| Age categorical<br>Units: participants    |        |     |  |
| Adults (18-64 years)                      | 51     | 205 |  |
| From 65-84 years                          | 25     | 93  |  |
| 85 years and over                         | 2      | 6   |  |
| Age Continuous<br>Units: years            |        |     |  |
| arithmetic mean                           | 57.1   |     |  |
| standard deviation                        | ± 14.2 | -   |  |
| Sex: Female, Male<br>Units: participants  |        |     |  |
| Female                                    | 34     | 132 |  |
| Male                                      | 44     | 172 |  |
| Race (NIH/OMB)<br>Units: Subjects         |        |     |  |
| American Indian or Alaska Native          | 2      | 6   |  |
| Asian                                     | 1      | 23  |  |
| Native Hawaiian or Other Pacific Islander | 0      | 1   |  |
| Black or African American                 | 7      | 18  |  |
| White                                     | 63     | 227 |  |
| More than one race                        | 5      | 27  |  |
| Unknown or Not Reported                   | 0      | 2   |  |
| Ethnicity (NIH/OMB)<br>Units: Subjects    |        |     |  |
| Hispanic or Latino                        | 27     | 114 |  |
| Not Hispanic or Latino                    | 49     | 184 |  |
| Unknown or Not Reported                   | 2      | 6   |  |

## End points

### End points reporting groups

|  |                             |
|--|-----------------------------|
| Reporting group title  | Part 1: Molnupiravir 200 mg |
| Reporting group description:<br>200 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)           |                             |
| Reporting group title  | Part 1: Molnupiravir 400 mg |
| Reporting group description:<br>400 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)           |                             |
| Reporting group title  | Part 1: Molnupiravir 800 mg |
| Reporting group description:<br>800 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)           |                             |
| Reporting group title  | Part 1: Placebo             |
| Reporting group description:<br>Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total) |                             |

### Primary: Time-to-sustained recovery

|  |                            |
|--|----------------------------|
| End point title  | Time-to-sustained recovery |
| End point description:<br>The median time to sustained recovery is reported. Sustained recovery is defined as 1) the participant is alive and not hospitalized; or 2) the participant is alive and medically ready for discharge as determined by the investigator. All randomized participants in Part 1 who received $\geq 1$ dose of study drug are included. |                            |
| End point type   | Primary                    |
| End point timeframe:<br>Up to 29 days  |                            |

| End point values                 | Part 1:<br>Molnupiravir<br>200 mg | Part 1:<br>Molnupiravir<br>400 mg | Part 1:<br>Molnupiravir<br>800 mg | Part 1: Placebo   |
|----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-------------------|
| Subject group type               | Reporting group                   | Reporting group                   | Reporting group                   | Reporting group   |
| Number of subjects analysed      | 73                                | 73                                | 72                                | 75                |
| Units: days                      |                                   |                                   |                                   |                   |
| median (confidence interval 95%) | 9.0 (7.0 to 10.0)                 | 9.0 (8.0 to 10.0)                 | 9.0 (8.0 to 11.0)                 | 9.0 (8.0 to 11.0) |

### Statistical analyses

|   |   |
|---|---|
| Statistical analysis title  | Time to Recovery: Molnupiravir 200 mg vs. Placebo |
| Statistical analysis description:<br>Based on Cox regression model with Efron's method of tie handling. |   |
| Comparison groups   | Part 1: Molnupiravir 200 mg v Part 1: Placebo     |

|   |                   |
|---|-------------------|
| Number of subjects included in analysis | 148               |
| Analysis specification                  | Pre-specified     |
| Analysis type                           | superiority       |
| P-value                                 | = 0.562           |
| Method                                  | Logrank           |
| Parameter estimate                      | Hazard ratio (HR) |
| Point estimate                          | 0.99              |
| Confidence interval                     |                   |
| level                                   | 95 %              |
| sides                                   | 2-sided           |
| lower limit                             | 0.68              |
| upper limit                             | 1.45              |

|   |   |
|---|---|
| <b>Statistical analysis title</b>   | Time to Recovery: Molnupiravir 800 mg vs. Placebo |
| Statistical analysis description:<br>Based on Cox regression model with Efron's method of tie handling. |   |
| Comparison groups   | Part 1: Molnupiravir 800 mg v Part 1: Placebo     |
| Number of subjects included in analysis   | 147   |
| Analysis specification  | Pre-specified                                     |
| Analysis type   | superiority                                       |
| P-value   | = 0.4894  |
| Method  | Logrank   |
| Parameter estimate  | Hazard ratio (HR)                                 |
| Point estimate  | 1.01  |
| Confidence interval   |   |
| level   | 95 %  |
| sides   | 2-sided   |
| lower limit   | 0.69  |
| upper limit   | 1.47  |

|   |   |
|---|---|
| <b>Statistical analysis title</b>   | Time to Recovery: Molnupiravir 400 mg vs. Placebo |
| Statistical analysis description:<br>Based on Cox regression model with Efron's method of tie handling. |   |
| Comparison groups   | Part 1: Molnupiravir 400 mg v Part 1: Placebo     |
| Number of subjects included in analysis   | 148   |
| Analysis specification  | Pre-specified                                     |
| Analysis type   | superiority                                       |
| P-value   | = 0.3145  |
| Method  | Logrank   |
| Parameter estimate  | Hazard ratio (HR)                                 |
| Point estimate  | 1.13  |
| Confidence interval   |   |
| level   | 95 %  |
| sides   | 2-sided   |
| lower limit   | 0.78  |
| upper limit   | 1.65  |

---

**Primary: Number of participants with an adverse event (AE)**

---

|                 |  |
|-----------------|--|
| End point title | Number of participants with an adverse event (AE) <sup>[1]</sup> |
|-----------------|--|

End point description:

The number of participants with at least 1 AE is presented. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. All randomized participants in Part 1 who received  $\geq 1$  dose of study drug are included.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to 19 days (during treatment and 14-day follow-up)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Per protocol, only descriptive statistics are presented.

| End point values            | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------|
| Subject group type          | Reporting group             | Reporting group             | Reporting group             | Reporting group |
| Number of subjects analysed | 73                          | 73                          | 72                          | 75              |
| Units: participants         | 40                          | 36                          | 45                          | 46              |

---

**Statistical analyses**

---

No statistical analyses for this end point

---

**Primary: Number of participants who discontinued study intervention due to an AE**

---

|                 |  |
|-----------------|--|
| End point title | Number of participants who discontinued study intervention due to an AE <sup>[2]</sup> |
|-----------------|--|

End point description:

The number of participants discontinuing from study treatment due to an AE is presented. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. All randomized participants in Part 1 who received  $\geq 1$  dose of study drug are included.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to 5 days

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Per protocol, only descriptive statistics are presented.

| End point values            | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------|
| Subject group type          | Reporting group             | Reporting group             | Reporting group             | Reporting group |
| Number of subjects analysed | 73                          | 73                          | 72                          | 75              |
| Units: participants         | 0                           | 1                           | 0                           | 0               |

## Statistical analyses

No statistical analyses for this end point

### Secondary: Number of participants with all-cause mortality

|  |   |
|--|---|
| End point title  | Number of participants with all-cause mortality |
| End point description:<br>The number of participants with all-cause mortality (ACM) through Day 29 is presented. All-cause mortality is defined as death due to any cause. Any participants with an unknown survival status at Day 29 were imputed as deceased. All randomized participants in Part 1 who received $\geq 1$ dose of study drug are included. |   |
| End point type   | Secondary                                       |
| End point timeframe:<br>Up to 29 days  |   |

| End point values            | Part 1:<br>Molnupiravir<br>200 mg | Part 1:<br>Molnupiravir<br>400 mg | Part 1:<br>Molnupiravir<br>800 mg | Part 1: Placebo |
|-----------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------|
| Subject group type          | Reporting group                   | Reporting group                   | Reporting group                   | Reporting group |
| Number of subjects analysed | 73                                | 73                                | 72                                | 75              |
| Units: participants         | 4                                 | 5                                 | 4                                 | 1               |

## Statistical analyses

|   |   |
|---|---|
| Statistical analysis title  | ACM: Molnupiravir 200 mg vs. Placebo          |
| Statistical analysis description:<br>Unknown Day 29 survival status was treated as failure. |   |
| Comparison groups   | Part 1: Molnupiravir 200 mg v Part 1: Placebo |
| Number of subjects included in analysis   | 148   |
| Analysis specification  | Pre-specified                                 |
| Analysis type   | superiority                                   |
| P-value   | = 0.1642                                      |
| Method  | Miettinen and Nurminen method                 |
| Parameter estimate  | Mean difference (final values)                |
| Point estimate  | 4.1   |
| Confidence interval   |   |
| level   | 95 %  |
| sides   | 2-sided                                       |
| lower limit   | -2.3  |
| upper limit   | 12.1  |

|   |   |
|---|---|
| <b>Statistical analysis title</b>   | ACM: Molnupiravir 400 mg vs. Placebo          |
| Statistical analysis description:<br>Unknown Day 29 survival status was treated as failure. |   |
| Comparison groups   | Part 1: Molnupiravir 400 mg v Part 1: Placebo |
| Number of subjects included in analysis   | 148   |
| Analysis specification  | Pre-specified                                 |
| Analysis type   | superiority                                   |
| P-value   | = 0.09  |
| Method  | Miettinen and Nurminen method                 |
| Parameter estimate  | Mean difference (final values)                |
| Point estimate  | 5.5   |
| Confidence interval   |   |
| level   | 95 %  |
| sides   | 2-sided                                       |
| lower limit   | -1.1  |
| upper limit   | 13.9  |

|   |   |
|---|---|
| <b>Statistical analysis title</b>   | ACM: Molnupiravir 800 mg vs. Placebo          |
| Statistical analysis description:<br>Unknown Day 29 survival status was treated as failure. |   |
| Comparison groups   | Part 1: Molnupiravir 800 mg v Part 1: Placebo |
| Number of subjects included in analysis   | 147   |
| Analysis specification  | Pre-specified                                 |
| Analysis type   | superiority                                   |
| P-value   | = 0.1594                                      |
| Method  | Miettinen and Nurminen method                 |
| Parameter estimate  | Mean difference (final values)                |
| Point estimate  | 4.2   |
| Confidence interval   |   |
| level   | 95 %  |
| sides   | 2-sided                                       |
| lower limit   | -2.3  |
| upper limit   | 12.3  |

### **Secondary: Odds of a more favorable response on Pulmonary ordinal outcome score on Day 3**

|                 |   |
|-----------------|---|
| End point title | Odds of a more favorable response on Pulmonary ordinal outcome score on Day 3 |
|-----------------|---|

End point description:

Pulmonary score is a score on an ordinal scale which focuses on respiratory sequelae based on oxygen requirements using 7 mutually exclusive categories. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequelae. The number of participants at each score category is presented. All randomized participants in Part 1 who received  $\geq 1$  dose of study drug and have data available at the relevant time point are included.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Day 3                |           |

| End point values            | Part 1:<br>Molnupiravir<br>200 mg | Part 1:<br>Molnupiravir<br>400 mg | Part 1:<br>Molnupiravir<br>800 mg | Part 1: Placebo |
|-----------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------|
| Subject group type          | Reporting group                   | Reporting group                   | Reporting group                   | Reporting group |
| Number of subjects analysed | 73                                | 73                                | 72                                | 75              |
| Units: participants         |                                   |                                   |                                   |                 |
| 1 (n=72,72,72,73)           | 25                                | 20                                | 21                                | 16              |
| 2 (n=72,72,72,73)           | 2                                 | 7                                 | 0                                 | 7               |
| 3 (n=72,72,72,73)           | 21                                | 20                                | 23                                | 25              |
| 4 (n=72,72,72,73)           | 16                                | 16                                | 19                                | 14              |
| 5 (n=72,72,72,73)           | 7                                 | 9                                 | 6                                 | 10              |
| 6 (n=72,72,72,73)           | 1                                 | 0                                 | 3                                 | 1               |
| 7 (n=72,72,72,73)           | 0                                 | 0                                 | 0                                 | 0               |
| Missing (n=73,73,72,75)     | 1                                 | 1                                 | 0                                 | 2               |

### Statistical analyses

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | Pulmonary Day 3: Molnupiravir 200 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 200 mg v Part 1: Placebo    |
| Number of subjects included in analysis | 148  |
| Analysis specification                  | Pre-specified                                    |
| Analysis type                           | superiority                                      |
| P-value                                 | = 0.3623   |
| Method                                  | Wald Chi-Square                                  |
| Parameter estimate                      | Odds ratio (OR)                                  |
| Point estimate                          | 1.31   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 0.73   |
| upper limit                             | 2.35   |

|                                   |  |
|-----------------------------------|--|
| <b>Statistical analysis title</b> | Pulmonary Day 3: Molnupiravir 800 mg vs. Placebo |
| Comparison groups                 | Part 1: Molnupiravir 800 mg v Part 1: Placebo    |

|   |                 |
|---|-----------------|
| Number of subjects included in analysis | 147             |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority     |
| P-value                                 | = 0.9313        |
| Method                                  | Wald Chi-Square |
| Parameter estimate                      | Odds ratio (OR) |
| Point estimate                          | 0.97            |
| Confidence interval                     |                 |
| level                                   | 95 %            |
| sides                                   | 2-sided         |
| lower limit                             | 0.54            |
| upper limit                             | 1.75            |

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | Pulmonary Day 3: Molnupiravir 400 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 400 mg v Part 1: Placebo    |
| Number of subjects included in analysis | 148  |
| Analysis specification                  | Pre-specified                                    |
| Analysis type                           | superiority                                      |
| P-value                                 | = 0.5714   |
| Method                                  | Wald Chi-Square                                  |
| Parameter estimate                      | Odds ratio (OR)                                  |
| Point estimate                          | 1.18   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 0.66   |
| upper limit                             | 2.12   |

### **Secondary: Odds of a more favorable response on Pulmonary ordinal outcome score on End of Treatment (EOT [Day 5])**

|                 |  |
|-----------------|--|
| End point title | Odds of a more favorable response on Pulmonary ordinal outcome score on End of Treatment (EOT [Day 5]) |
|-----------------|--|

#### **End point description:**

Pulmonary score is a score on an ordinal scale which focuses on respiratory sequelae based on oxygen requirements using 7 mutually exclusive categories. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequelae. The number of participants at each score category is presented. All randomized participants in Part 1 who received  $\geq 1$  dose of study drug and have data available at the relevant time point are included.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

#### **End point timeframe:**

EOT (Day 5)

| End point values            | Part 1:<br>Molnupiravir<br>200 mg | Part 1:<br>Molnupiravir<br>400 mg | Part 1:<br>Molnupiravir<br>800 mg | Part 1: Placebo |
|-----------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------|
| Subject group type          | Reporting group                   | Reporting group                   | Reporting group                   | Reporting group |
| Number of subjects analysed | 73                                | 73                                | 72                                | 75              |
| Units: participants         |                                   |                                   |                                   |                 |
| 1 (n=71,68,70,70)           | 30                                | 22                                | 26                                | 27              |
| 2 (n=71,68,70,70)           | 6                                 | 5                                 | 4                                 | 4               |
| 3 (n=71,68,70,70)           | 17                                | 18                                | 15                                | 16              |
| 4 (n=71,68,70,70)           | 10                                | 14                                | 14                                | 14              |
| 5 (n=71,68,70,70)           | 7                                 | 8                                 | 8                                 | 8               |
| 6 (n=71,68,70,70)           | 1                                 | 1                                 | 3                                 | 1               |
| 7 (n=71,68,70,70)           | 0                                 | 0                                 | 0                                 | 0               |
| Missing (n=73,73,72,75)     | 2                                 | 5                                 | 2                                 | 5               |

## Statistical analyses

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | Pulmonary Day 5: Molnupiravir 200 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 200 mg v Part 1: Placebo    |
| Number of subjects included in analysis | 148  |
| Analysis specification                  | Pre-specified                                    |
| Analysis type                           | superiority                                      |
| P-value                                 | = 0.4398   |
| Method                                  | Wald Chi-Square                                  |
| Parameter estimate                      | Odds ratio (OR)                                  |
| Point estimate                          | 1.27   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 0.7  |
| upper limit                             | 2.3  |

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | Pulmonary Day 5: Molnupiravir 800 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 800 mg v Part 1: Placebo    |
| Number of subjects included in analysis | 147  |
| Analysis specification                  | Pre-specified                                    |
| Analysis type                           | superiority                                      |
| P-value                                 | = 0.7069   |
| Method                                  | Wald Chi-Square                                  |
| Parameter estimate                      | Odds ratio (OR)                                  |
| Point estimate                          | 0.89   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 0.49   |
| upper limit                             | 1.62   |

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | Pulmonary Day 5: Molnupiravir 400 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 400 mg v Part 1: Placebo    |
| Number of subjects included in analysis | 148  |
| Analysis specification                  | Pre-specified                                    |
| Analysis type                           | superiority                                      |
| P-value                                 | = 0.6277   |
| Method                                  | Wald Chi-Square                                  |
| Parameter estimate                      | Odds ratio (OR)                                  |
| Point estimate                          | 0.86   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 0.47   |
| upper limit                             | 1.57   |

### Secondary: Odds of a more favorable response on Pulmonary ordinal outcome score on Day 10

|                 |  |
|-----------------|--|
| End point title | Odds of a more favorable response on Pulmonary ordinal outcome score on Day 10 |
|-----------------|--|

End point description:

Pulmonary score is a score on an ordinal scale which focuses on respiratory sequelae based on oxygen requirements using 7 mutually exclusive categories. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequelae. The number of participants at each score category is presented. All randomized participants in Part 1 who received  $\geq 1$  dose of study drug and have data available at the relevant time point are included.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 10

| <b>End point values</b>     | Part 1:<br>Molnupiravir<br>200 mg | Part 1:<br>Molnupiravir<br>400 mg | Part 1:<br>Molnupiravir<br>800 mg | Part 1: Placebo |
|-----------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------|
| Subject group type          | Reporting group                   | Reporting group                   | Reporting group                   | Reporting group |
| Number of subjects analysed | 73                                | 73                                | 72                                | 75              |
| Units: participants         |                                   |                                   |                                   |                 |
| 1 (n=68,64,67,70)           | 44                                | 39                                | 33                                | 38              |
| 2 (n=68,64,67,70)           | 4                                 | 4                                 | 4                                 | 5               |
| 3 (n=68,64,67,70)           | 8                                 | 8                                 | 14                                | 10              |
| 4 (n=68,64,67,70)           | 5                                 | 7                                 | 8                                 | 10              |
| 5 (n=68,64,67,70)           | 4                                 | 3                                 | 5                                 | 4               |
| 6 (n=68,64,67,70)           | 3                                 | 0                                 | 3                                 | 3               |
| 7 (n=68,64,67,70)           | 0                                 | 3                                 | 0                                 | 0               |
| Missing (n=73,73,72,75)     | 5                                 | 9                                 | 5                                 | 5               |

## Statistical analyses

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Pulmonary Day 10: Molnupiravir 200 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 200 mg v Part 1: Placebo     |
| Number of subjects included in analysis | 148   |
| Analysis specification                  | Pre-specified                                     |
| Analysis type                           | superiority                                       |
| P-value                                 | = 0.2422  |
| Method                                  | Wald Chi-Square                                   |
| Parameter estimate                      | Odds ratio (OR)                                   |
| Point estimate                          | 1.48  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 0.77  |
| upper limit                             | 2.85  |

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Pulmonary Day 10: Molnupiravir 400 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 400 mg v Part 1: Placebo     |
| Number of subjects included in analysis | 148   |
| Analysis specification                  | Pre-specified                                     |
| Analysis type                           | superiority                                       |
| P-value                                 | = 0.4789  |
| Method                                  | Wald Chi-Square                                   |
| Parameter estimate                      | Odds ratio (OR)                                   |
| Point estimate                          | 1.27  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 0.66  |
| upper limit                             | 2.44  |

|                                   |   |
|-----------------------------------|---|
| <b>Statistical analysis title</b> | Pulmonary Day 10: Molnupiravir 800 mg vs. Placebo |
| Comparison groups                 | Part 1: Molnupiravir 800 mg v Part 1: Placebo     |

|   |                 |
|---|-----------------|
| Number of subjects included in analysis | 147             |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority     |
| P-value                                 | = 0.6052        |
| Method                                  | Wald Chi-Square |
| Parameter estimate                      | Odds ratio (OR) |
| Point estimate                          | 0.85            |
| Confidence interval                     |                 |
| level                                   | 95 %            |
| sides                                   | 2-sided         |
| lower limit                             | 0.45            |
| upper limit                             | 1.59            |

## Secondary: Odds of a more favorable response on Pulmonary ordinal outcome score on Day 15

|                 |  |
|-----------------|--|
| End point title | Odds of a more favorable response on Pulmonary ordinal outcome score on Day 15 |
|-----------------|--|

End point description:

Pulmonary score is a score on an ordinal scale which focuses on respiratory sequelae based on oxygen requirements using 7 mutually exclusive categories. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequelae. The number of participants at each score category is presented. All randomized participants in Part 1 who received  $\geq 1$  dose of study drug and have data available at the relevant time point are included.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 15

| End point values            | Part 1:<br>Molnupiravir<br>200 mg | Part 1:<br>Molnupiravir<br>400 mg | Part 1:<br>Molnupiravir<br>800 mg | Part 1: Placebo |
|-----------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------|
| Subject group type          | Reporting group                   | Reporting group                   | Reporting group                   | Reporting group |
| Number of subjects analysed | 73                                | 73                                | 72                                | 75              |
| Units: participants         |                                   |                                   |                                   |                 |
| 1 (n=67,62,68,71)           | 45                                | 44                                | 41                                | 42              |
| 2 (n=67,62,68,71)           | 7                                 | 2                                 | 2                                 | 5               |
| 3 (n=67,62,68,71)           | 6                                 | 6                                 | 14                                | 10              |
| 4 (n=67,62,68,71)           | 3                                 | 5                                 | 3                                 | 6               |
| 5 (n=67,62,68,71)           | 2                                 | 1                                 | 0                                 | 4               |
| 6 (n=67,62,68,71)           | 4                                 | 1                                 | 7                                 | 3               |
| 7 (n=67,62,68,71)           | 0                                 | 3                                 | 1                                 | 1               |
| Missing (n=73,73,72,75)     | 6                                 | 11                                | 4                                 | 4               |

## Statistical analyses

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Pulmonary Day 15: Molnupiravir 200 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 200 mg v Part 1: Placebo     |
| Number of subjects included in analysis | 148   |
| Analysis specification                  | Pre-specified                                     |
| Analysis type                           | superiority                                       |
| P-value                                 | = 0.2644  |
| Method                                  | Wald Chi-Square                                   |
| Parameter estimate                      | Odds ratio (OR)                                   |
| Point estimate                          | 1.47  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 0.75  |
| upper limit                             | 2.88  |

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Pulmonary Day 15: Molnupiravir 400 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 400 mg v Part 1: Placebo     |
| Number of subjects included in analysis | 148   |
| Analysis specification                  | Pre-specified                                     |
| Analysis type                           | superiority                                       |
| P-value                                 | = 0.2184  |
| Method                                  | Wald Chi-Square                                   |
| Parameter estimate                      | Odds ratio (OR)                                   |
| Point estimate                          | 1.55  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 0.77  |
| upper limit                             | 3.14  |

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Pulmonary Day 15: Molnupiravir 800 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 800 mg v Part 1: Placebo     |
| Number of subjects included in analysis | 147   |
| Analysis specification                  | Pre-specified                                     |
| Analysis type                           | superiority                                       |
| P-value                                 | = 0.9771  |
| Method                                  | Wald Chi-Square                                   |
| Parameter estimate                      | Odds ratio (OR)                                   |
| Point estimate                          | 1.01  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 0.53  |
| upper limit                             | 1.94  |

**Secondary: Odds of a more favorable response on Pulmonary ordinal outcome score on Day 29**

|                 |  |
|-----------------|--|
| End point title | Odds of a more favorable response on Pulmonary ordinal outcome score on Day 29 |
|-----------------|--|

**End point description:**

Pulmonary score is a score on an ordinal scale which focuses on respiratory sequelae based on oxygen requirements using 7 mutually exclusive categories. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequelae. The number of participants at each score category is presented. All randomized participants in Part 1 who received  $\geq 1$  dose of study drug and have data available at the relevant time point are included.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

**End point timeframe:**

Day 29

| <b>End point values</b>     | Part 1:<br>Molnupiravir<br>200 mg | Part 1:<br>Molnupiravir<br>400 mg | Part 1:<br>Molnupiravir<br>800 mg | Part 1: Placebo |
|-----------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------|
| Subject group type          | Reporting group                   | Reporting group                   | Reporting group                   | Reporting group |
| Number of subjects analysed | 73                                | 73                                | 72                                | 75              |
| Units: participants         |                                   |                                   |                                   |                 |
| 1 (n=63,59,69,69)           | 46                                | 47                                | 47                                | 49              |
| 2 (n=63,59,69,69)           | 2                                 | 2                                 | 2                                 | 5               |
| 3 (n=63,59,69,69)           | 4                                 | 5                                 | 9                                 | 7               |
| 4 (n=63,59,69,69)           | 5                                 | 1                                 | 3                                 | 5               |
| 5 (n=63,59,69,69)           | 0                                 | 0                                 | 0                                 | 0               |
| 6 (n=63,59,69,69)           | 2                                 | 0                                 | 5                                 | 2               |
| 7 (n=63,59,69,69)           | 4                                 | 4                                 | 3                                 | 1               |
| Missing (n=73,73,72,75)     | 10                                | 14                                | 3                                 | 6               |

**Statistical analyses**

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Pulmonary Day 29: Molnupiravir 200 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 200 mg v Part 1: Placebo     |
| Number of subjects included in analysis | 148   |
| Analysis specification                  | Pre-specified                                     |
| Analysis type                           | superiority                                       |
| P-value                                 | = 0.9945  |
| Method                                  | Wald Chi-Square                                   |
| Parameter estimate                      | Odds ratio (OR)                                   |
| Point estimate                          | 0.97  |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 95 %    |
| sides               | 2-sided |
| lower limit         | 0.46    |
| upper limit         | 2.06    |

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Pulmonary Day 15: Molnupiravir 400 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 400 mg v Part 1: Placebo     |
| Number of subjects included in analysis | 148   |
| Analysis specification                  | Pre-specified                                     |
| Analysis type                           | superiority                                       |
| P-value                                 | = 0.3227  |
| Method                                  | Wald Chi-Square                                   |
| Parameter estimate                      | Odds ratio (OR)                                   |
| Point estimate                          | 1.5   |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 0.67  |
| upper limit                             | 3.37  |

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Pulmonary Day 15: Molnupiravir 800 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 800 mg v Part 1: Placebo     |
| Number of subjects included in analysis | 147   |
| Analysis specification                  | Pre-specified                                     |
| Analysis type                           | superiority                                       |
| P-value                                 | = 0.52  |
| Method                                  | Wald Chi-Square                                   |
| Parameter estimate                      | Odds ratio (OR)                                   |
| Point estimate                          | 0.79  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 0.39  |
| upper limit                             | 1.61  |

### **Secondary: Odds of a more favorable response on Pulmonary+ ordinal outcome score on Day 3**

|                 |  |
|-----------------|--|
| End point title | Odds of a more favorable response on Pulmonary+ ordinal outcome score on Day 3 |
|-----------------|--|

End point description:

Pulmonary+ score is a score on an ordinal scale which is a 7-category assessment that captures the range of disease severity in hospitalized participants, including coagulation-related complications and respiratory dysfunction. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory

sequae. The number of participants at each score category is presented. All randomized participants in Part 1 who received  $\geq 1$  dose of study drug and have data available at the relevant time point are included.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Day 3                |           |

| End point values            | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------|
| Subject group type          | Reporting group             | Reporting group             | Reporting group             | Reporting group |
| Number of subjects analysed | 73                          | 73                          | 72                          | 75              |
| Units: participants         |                             |                             |                             |                 |
| 1 (n=72,72,72,73)           | 25                          | 20                          | 21                          | 16              |
| 2 (n=72,72,72,73)           | 2                           | 7                           | 0                           | 7               |
| 3 (n=72,72,72,73)           | 20                          | 20                          | 23                          | 25              |
| 4 (n=72,72,72,73)           | 16                          | 16                          | 19                          | 14              |
| 5 (n=72,72,72,73)           | 7                           | 9                           | 6                           | 10              |
| 6 (n=72,72,72,73)           | 2                           | 0                           | 3                           | 1               |
| 7 (n=72,72,72,73)           | 0                           | 0                           | 0                           | 0               |
| Missing (n=73,73,72,75)     | 1                           | 1                           | 0                           | 2               |

## Statistical analyses

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Pulmonary+ Day 3: Molnupiravir 200 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 200 mg v Part 1: Placebo     |
| Number of subjects included in analysis | 148   |
| Analysis specification                  | Pre-specified                                     |
| Analysis type                           | superiority                                       |
| P-value                                 | = 0.4472  |
| Method                                  | Wald Chi-Square                                   |
| Parameter estimate                      | Odds ratio (OR)                                   |
| Point estimate                          | 1.25  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 0.7   |
| upper limit                             | 2.25  |

|                                   |   |
|-----------------------------------|---|
| <b>Statistical analysis title</b> | Pulmonary+ Day 3: Molnupiravir 800 mg vs. Placebo |
| Comparison groups                 | Part 1: Molnupiravir 800 mg v Part 1: Placebo     |

|   |                 |
|---|-----------------|
| Number of subjects included in analysis | 147             |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority     |
| P-value                                 | = 0.9313        |
| Method                                  | Wald Chi-Square |
| Parameter estimate                      | Odds ratio (OR) |
| Point estimate                          | 0.97            |
| Confidence interval                     |                 |
| level                                   | 95 %            |
| sides                                   | 2-sided         |
| lower limit                             | 0.54            |
| upper limit                             | 1.75            |

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Pulmonary+ Day 3: Molnupiravir 400 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 400 mg v Part 1: Placebo     |
| Number of subjects included in analysis | 148   |
| Analysis specification                  | Pre-specified                                     |
| Analysis type                           | superiority                                       |
| P-value                                 | = 0.5714  |
| Method                                  | Wald Chi-Square                                   |
| Parameter estimate                      | Odds ratio (OR)                                   |
| Point estimate                          | 1.18  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 0.66  |
| upper limit                             | 2.12  |

### **Secondary: Odds of a more favorable response on Pulmonary+ ordinal outcome score on EOT (Day 5)**

|                 |  |
|-----------------|--|
| End point title | Odds of a more favorable response on Pulmonary+ ordinal outcome score on EOT (Day 5) |
|-----------------|--|

End point description:

Pulmonary+ score is a score on an ordinal scale which is a 7-category assessment that captures the range of disease severity in hospitalized participants, including coagulation-related complications and respiratory dysfunction. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequelae. The number of participants at each score category is presented. All randomized participants in Part 1 who received  $\geq 1$  dose of study drug and have data available at the relevant time point are included.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

EOT (Day 5)

| End point values            | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------|
| Subject group type          | Reporting group             | Reporting group             | Reporting group             | Reporting group |
| Number of subjects analysed | 73                          | 73                          | 72                          | 75              |
| Units: participants         |                             |                             |                             |                 |
| 1 (n=71,68,70,70)           | 30                          | 22                          | 26                          | 27              |
| 2 (n=71,68,70,70)           | 6                           | 5                           | 4                           | 4               |
| 3 (n=71,68,70,70)           | 16                          | 18                          | 15                          | 16              |
| 4 (n=71,68,70,70)           | 10                          | 14                          | 14                          | 14              |
| 5 (n=71,68,70,70)           | 7                           | 8                           | 8                           | 8               |
| 6 (n=71,68,70,70)           | 2                           | 1                           | 3                           | 1               |
| 7 (n=71,68,70,70)           | 0                           | 0                           | 0                           | 0               |
| Missing (n=73,73,72,75)     | 2                           | 5                           | 2                           | 5               |

## Statistical analyses

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Pulmonary+ Day 5: Molnupiravir 200 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 200 mg v Part 1: Placebo     |
| Number of subjects included in analysis | 148   |
| Analysis specification                  | Pre-specified                                     |
| Analysis type                           | superiority                                       |
| P-value                                 | = 0.5222  |
| Method                                  | Wald Chi-Square                                   |
| Parameter estimate                      | Odds ratio (OR)                                   |
| Point estimate                          | 1.22  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 0.67  |
| upper limit                             | 2.21  |

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Pulmonary+ Day 5: Molnupiravir 400 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 400 mg v Part 1: Placebo     |
| Number of subjects included in analysis | 148   |
| Analysis specification                  | Pre-specified                                     |
| Analysis type                           | superiority                                       |
| P-value                                 | = 0.6277  |
| Method                                  | Wald Chi-Square                                   |
| Parameter estimate                      | Odds ratio (OR)                                   |
| Point estimate                          | 0.86  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 0.47  |
| upper limit                             | 1.57  |

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | Pulmonary+ Day 5: Molnupiravir 800 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 800 mg v Part 1: Placebo     |
| Number of subjects included in analysis | 147   |
| Analysis specification                  | Pre-specified                                     |
| Analysis type                           | superiority                                       |
| P-value                                 | = 0.7069  |
| Method                                  | Wald Chi-Square                                   |
| Parameter estimate                      | Odds ratio (OR)                                   |
| Point estimate                          | 0.89  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided   |
| lower limit                             | 0.49  |
| upper limit                             | 1.62  |

### Secondary: Odds of a more favorable response on Pulmonary+ ordinal outcome score on Day 10

|                 |   |
|-----------------|---|
| End point title | Odds of a more favorable response on Pulmonary+ ordinal outcome score on Day 10 |
|-----------------|---|

End point description:

Pulmonary+ score is a score on an ordinal scale which is a 7-category assessment that captures the range of disease severity in hospitalized participants, including coagulation-related complications and respiratory dysfunction. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequelae. The number of participants at each score category is presented. All randomized participants in Part 1 who received  $\geq 1$  dose of study drug and have data available at the relevant time point are included.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 10

| <b>End point values</b>     | Part 1:<br>Molnupiravir<br>200 mg | Part 1:<br>Molnupiravir<br>400 mg | Part 1:<br>Molnupiravir<br>800 mg | Part 1: Placebo |
|-----------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------|
| Subject group type          | Reporting group                   | Reporting group                   | Reporting group                   | Reporting group |
| Number of subjects analysed | 73                                | 73                                | 72                                | 75              |
| Units: participants         |                                   |                                   |                                   |                 |
| 1 (n=68,64,67,70)           | 44                                | 39                                | 33                                | 38              |
| 2 (n=68,64,67,70)           | 4                                 | 4                                 | 4                                 | 5               |
| 3 (n=68,64,67,70)           | 8                                 | 8                                 | 14                                | 10              |
| 4 (n=68,64,67,70)           | 4                                 | 7                                 | 8                                 | 10              |
| 5 (n=68,64,67,70)           | 4                                 | 3                                 | 4                                 | 4               |
| 6 (n=68,64,67,70)           | 4                                 | 0                                 | 4                                 | 3               |
| 7 (n=68,64,67,70)           | 0                                 | 3                                 | 0                                 | 0               |
| Missing (n=73,73,72,75)     | 5                                 | 9                                 | 5                                 | 5               |

## Statistical analyses

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | Pulmonary+ Day 10: Molnupiravir 200 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 200 mg v Part 1: Placebo      |
| Number of subjects included in analysis | 148  |
| Analysis specification                  | Pre-specified                                      |
| Analysis type                           | superiority  |
| P-value                                 | = 0.2627   |
| Method                                  | Wald Chi-Square                                    |
| Parameter estimate                      | Odds ratio (OR)                                    |
| Point estimate                          | 1.46   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 0.75   |
| upper limit                             | 2.8  |

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | Pulmonary+ Day 10: Molnupiravir 800 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 800 mg v Part 1: Placebo      |
| Number of subjects included in analysis | 147  |
| Analysis specification                  | Pre-specified                                      |
| Analysis type                           | superiority  |
| P-value                                 | = 0.5938   |
| Method                                  | Wald Chi-Square                                    |
| Parameter estimate                      | Odds ratio (OR)                                    |
| Point estimate                          | 0.84   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 0.45   |
| upper limit                             | 1.58   |

|                                   |  |
|-----------------------------------|--|
| <b>Statistical analysis title</b> | Pulmonary+ Day 10: Molnupiravir 400 mg vs. Placebo |
| Comparison groups                 | Part 1: Molnupiravir 400 mg v Part 1: Placebo      |

|   |                 |
|---|-----------------|
| Number of subjects included in analysis | 148             |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority     |
| P-value                                 | = 0.4789        |
| Method                                  | Wald Chi-Square |
| Parameter estimate                      | Odds ratio (OR) |
| Point estimate                          | 1.27            |
| Confidence interval                     |                 |
| level                                   | 95 %            |
| sides                                   | 2-sided         |
| lower limit                             | 0.66            |
| upper limit                             | 2.44            |

### Secondary: Odds of a more favorable response on Pulmonary+ ordinal outcome score on Day 15

|                 |   |
|-----------------|---|
| End point title | Odds of a more favorable response on Pulmonary+ ordinal outcome score on Day 15 |
|-----------------|---|

End point description:

Pulmonary+ score is a score on an ordinal scale which is a 7-category assessment that captures the range of disease severity in hospitalized participants, including coagulation-related complications and respiratory dysfunction. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequelae. The number of participants at each score category is presented. All randomized participants in Part 1 who received  $\geq 1$  dose of study drug and have data available at the relevant time point are included.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 15

| End point values            | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------|
| Subject group type          | Reporting group             | Reporting group             | Reporting group             | Reporting group |
| Number of subjects analysed | 73                          | 73                          | 72                          | 75              |
| Units: participants         |                             |                             |                             |                 |
| 1 (n=67,62,68,71)           | 45                          | 44                          | 41                          | 42              |
| 2 (n=67,62,68,71)           | 7                           | 2                           | 2                           | 5               |
| 3 (n=67,62,68,71)           | 6                           | 6                           | 14                          | 10              |
| 4 (n=67,62,68,71)           | 3                           | 5                           | 3                           | 6               |
| 5 (n=67,62,68,71)           | 2                           | 1                           | 0                           | 4               |
| 6 (n=67,62,68,71)           | 4                           | 1                           | 7                           | 3               |
| 7 (n=67,62,68,71)           | 0                           | 3                           | 1                           | 1               |
| Missing (n=73,73,72,75)     | 6                           | 11                          | 4                           | 4               |

### Statistical analyses

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | Pulmonary+ Day 15: Molnupiravir 200 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 200 mg v Part 1: Placebo      |
| Number of subjects included in analysis | 148  |
| Analysis specification                  | Pre-specified                                      |
| Analysis type                           | superiority  |
| P-value                                 | = 0.2644   |
| Method                                  | Wald Chi-Square                                    |
| Parameter estimate                      | Odds ratio (OR)                                    |
| Point estimate                          | 1.47   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 0.75   |
| upper limit                             | 2.88   |

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | Pulmonary+ Day 15: Molnupiravir 400 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 400 mg v Part 1: Placebo      |
| Number of subjects included in analysis | 148  |
| Analysis specification                  | Pre-specified                                      |
| Analysis type                           | superiority  |
| P-value                                 | = 0.2184   |
| Method                                  | Wald Chi-Square                                    |
| Parameter estimate                      | Odds ratio (OR)                                    |
| Point estimate                          | 1.55   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 0.77   |
| upper limit                             | 3.14   |

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | Pulmonary+ Day 15: Molnupiravir 800 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 800 mg v Part 1: Placebo      |
| Number of subjects included in analysis | 147  |
| Analysis specification                  | Pre-specified                                      |
| Analysis type                           | superiority  |
| P-value                                 | = 0.9771   |
| Method                                  | Wald Chi-Square                                    |
| Parameter estimate                      | Odds ratio (OR)                                    |
| Point estimate                          | 1.01   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 0.53   |
| upper limit                             | 1.94   |

## Secondary: Odds of a more favorable response on Pulmonary+ ordinal outcome score on Day 29

|                 |   |
|-----------------|---|
| End point title | Odds of a more favorable response on Pulmonary+ ordinal outcome score on Day 29 |
|-----------------|---|

End point description:

Pulmonary+ score is a score on an ordinal scale which is a 7-category assessment that captures the range of disease severity in hospitalized participants, including coagulation-related complications and respiratory dysfunction. The score ranges from 1 ("can independently undertake personal usual activities with minimal or no symptoms") to 7 ("death") with a higher score indicating more severe respiratory sequelae. The number of participants at each score category is presented. All randomized participants in Part 1 who received  $\geq 1$  dose of study drug and have data available at the relevant time point are included.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 29

| End point values            | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------|
| Subject group type          | Reporting group             | Reporting group             | Reporting group             | Reporting group |
| Number of subjects analysed | 73                          | 73                          | 72                          | 75              |
| Units: participants         |                             |                             |                             |                 |
| 1 (n=63,59,69,69)           | 46                          | 47                          | 47                          | 49              |
| 2 (n=63,59,69,69)           | 2                           | 2                           | 2                           | 5               |
| 3 (n=63,59,69,69)           | 4                           | 5                           | 9                           | 7               |
| 4 (n=63,59,69,69)           | 5                           | 1                           | 3                           | 5               |
| 5 (n=63,59,69,69)           | 0                           | 0                           | 0                           | 0               |
| 6 (n=63,59,69,69)           | 2                           | 0                           | 5                           | 2               |
| 7 (n=63,59,69,69)           | 4                           | 4                           | 3                           | 1               |
| Missing (n=63,59,69,69)     | 10                          | 14                          | 3                           | 6               |

## Statistical analyses

|   |  |
|---|--|
| Statistical analysis title              | Pulmonary+ Day 29: Molnupiravir 200 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 200 mg v Part 1: Placebo      |
| Number of subjects included in analysis | 148  |
| Analysis specification                  | Pre-specified                                      |
| Analysis type                           | superiority  |
| P-value                                 | = 0.9445   |
| Method                                  | Wald Chi-Square                                    |
| Parameter estimate                      | Odds ratio (OR)                                    |
| Point estimate                          | 0.97   |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 95 %    |
| sides               | 2-sided |
| lower limit         | 0.46    |
| upper limit         | 2.06    |

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | Pulmonary+ Day 29: Molnupiravir 400 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 400 mg v Part 1: Placebo      |
| Number of subjects included in analysis | 148  |
| Analysis specification                  | Pre-specified                                      |
| Analysis type                           | superiority  |
| P-value                                 | = 0.3227   |
| Method                                  | Wald Chi-Square                                    |
| Parameter estimate                      | Odds ratio (OR)                                    |
| Point estimate                          | 1.5  |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 0.67   |
| upper limit                             | 3.37   |

|   |  |
|---|--|
| <b>Statistical analysis title</b>       | Pulmonary+ Day 29: Molnupiravir 800 mg vs. Placebo |
| Comparison groups                       | Part 1: Molnupiravir 800 mg v Part 1: Placebo      |
| Number of subjects included in analysis | 147  |
| Analysis specification                  | Pre-specified                                      |
| Analysis type                           | superiority  |
| P-value                                 | = 0.52   |
| Method                                  | Wald Chi-Square                                    |
| Parameter estimate                      | Odds ratio (OR)                                    |
| Point estimate                          | 0.79   |
| Confidence interval                     |  |
| level                                   | 95 %   |
| sides                                   | 2-sided  |
| lower limit                             | 0.39   |
| upper limit                             | 1.61   |

### **Secondary: Odds of a more favorable response in the clinical risk of mortality category from the National Early Warning Score (NEWS)**

|                 |   |
|-----------------|---|
| End point title | Odds of a more favorable response in the clinical risk of mortality category from the National Early Warning Score (NEWS) |
|-----------------|---|

End point description:

NEWS (Royal College of Physicians, 2012) assesses a participant's degree of illness as assessed by clinical risk prediction categories based on a set of vital sign measurements. There are 7 physiological parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse

rate, level of consciousness, and temperature. A score of 0 to 3 was allocated to each parameter except supplemental oxygen use (score of 0 [no] or 2 [yes]) and level of consciousness (score of 0 or 3 with 0 = normal health condition and 3 = worst health condition). All scores were summed to get an aggregate score. Aggregate NEWS score ranged from 0 to 19, with higher scores meaning more severity/higher risk: low risk (score 0 to 4); low to medium risk (score of 3 in any individual parameter); medium risk (score 5 to 6); high risk (score 7 to 19). All randomized participants in Part 1 who received  $\geq 1$  dose of study drug and have data at the relevant time point are included.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| EOT (Day 5)          |           |

| End point values            | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------|
| Subject group type          | Reporting group             | Reporting group             | Reporting group             | Reporting group |
| Number of subjects analysed | 73                          | 73                          | 72                          | 75              |
| Units: participants         |                             |                             |                             |                 |
| Low (n=70,64,69,69)         | 57                          | 45                          | 52                          | 55              |
| Medium (n=70,64,69,69)      | 8                           | 8                           | 9                           | 11              |
| High (n=70,64,69,69)        | 5                           | 11                          | 8                           | 3               |
| Missing (n=70,64,69,69)     | 3                           | 9                           | 3                           | 6               |

### Statistical analyses

|   |   |
|---|---|
| Statistical analysis title              | NEWS: Molnupiravir 200 mg vs. Placebo         |
| Comparison groups                       | Part 1: Molnupiravir 200 mg v Part 1: Placebo |
| Number of subjects included in analysis | 148   |
| Analysis specification                  | Pre-specified                                 |
| Analysis type                           | superiority                                   |
| P-value                                 | = 0.8732                                      |
| Method                                  | Wald Chi-Square                               |
| Parameter estimate                      | Odds ratio (OR)                               |
| Point estimate                          | 1.07  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided                                       |
| lower limit                             | 0.46  |
| upper limit                             | 2.47  |

|                            |   |
|----------------------------|---|
| Statistical analysis title | NEWS: Molnupiravir 400 mg vs. Placebo         |
| Comparison groups          | Part 1: Molnupiravir 400 mg v Part 1: Placebo |

|   |                 |
|---|-----------------|
| Number of subjects included in analysis | 148             |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority     |
| P-value                                 | = 0.1277        |
| Method                                  | Wald Chi-square |
| Parameter estimate                      | Odds ratio (OR) |
| Point estimate                          | 0.54            |
| Confidence interval                     |                 |
| level                                   | 95 %            |
| sides                                   | 2-sided         |
| lower limit                             | 0.25            |
| upper limit                             | 1.19            |

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | NEWS: Molnupiravir 800 mg vs. Placebo         |
| Comparison groups                       | Part 1: Molnupiravir 800 mg v Part 1: Placebo |
| Number of subjects included in analysis | 147   |
| Analysis specification                  | Pre-specified                                 |
| Analysis type                           | superiority                                   |
| P-value                                 | = 0.4326                                      |
| Method                                  | Wald Chi-Square                               |
| Parameter estimate                      | Odds ratio (OR)                               |
| Point estimate                          | 0.73  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided                                       |
| lower limit                             | 0.33  |
| upper limit                             | 1.61  |

### **Secondary: Odds of a more favorable response on WHO 11-point ordinal outcomes score on a scale on Day 3**

|                 |  |
|-----------------|--|
| End point title | Odds of a more favorable response on WHO 11-point ordinal outcomes score on a scale on Day 3 |
|-----------------|--|

End point description:

The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented. All randomized participants in Part 1 who received  $\geq 1$  dose of study drug and have data at the relevant time point are included.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 3

| End point values            | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------|
| Subject group type          | Reporting group             | Reporting group             | Reporting group             | Reporting group |
| Number of subjects analysed | 73                          | 73                          | 72                          | 75              |
| Units: participants         |                             |                             |                             |                 |
| 0 (n=73,73,72,75)           | 0                           | 0                           | 0                           | 0               |
| 1 (n=73,73,72,75)           | 0                           | 0                           | 0                           | 0               |
| 2 (n=73,73,72,75)           | 1                           | 1                           | 0                           | 2               |
| 3 (n=73,73,72,75)           | 1                           | 0                           | 0                           | 1               |
| 4 (n=73,73,72,75)           | 27                          | 27                          | 21                          | 24              |
| 5 (n=73,73,72,75)           | 36                          | 36                          | 42                          | 37              |
| 6 (n=73,73,72,75)           | 7                           | 9                           | 6                           | 10              |
| 7 (n=73,73,72,75)           | 0                           | 0                           | 0                           | 0               |
| 8 (n=73,73,72,75)           | 0                           | 0                           | 2                           | 0               |
| 9 (n=73,73,72,75)           | 1                           | 0                           | 1                           | 1               |
| 10 (n=73,73,72,75)          | 0                           | 0                           | 0                           | 0               |
| Missing (n=73,73,72,75)     | 0                           | 0                           | 0                           | 0               |

## Statistical analyses

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | WHO Day 3: Molnupiravir 200 mg vs. Placebo    |
| Comparison groups                       | Part 1: Molnupiravir 200 mg v Part 1: Placebo |
| Number of subjects included in analysis | 148   |
| Analysis specification                  | Pre-specified                                 |
| Analysis type                           | superiority                                   |
| P-value                                 | = 0.683                                       |
| Method                                  | Wald Chi-Square                               |
| Parameter estimate                      | Odds ratio (OR)                               |
| Point estimate                          | 1.2   |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided                                       |
| lower limit                             | 0.5   |
| upper limit                             | 2.88  |

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | WHO Day 3: Molnupiravir 800 mg vs. Placebo    |
| Comparison groups                       | Part 1: Molnupiravir 800 mg v Part 1: Placebo |
| Number of subjects included in analysis | 147   |
| Analysis specification                  | Pre-specified                                 |
| Analysis type                           | superiority                                   |
| P-value                                 | = 0.8244                                      |
| Method                                  | Wald Chi-Square                               |
| Parameter estimate                      | Odds ratio (OR)                               |
| Point estimate                          | 0.9   |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 95 %    |
| sides               | 2-sided |
| lower limit         | 0.37    |
| upper limit         | 2.2     |

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | WHO Day 3: Molnupiravir 400 mg vs. Placebo    |
| Comparison groups                       | Part 1: Molnupiravir 400 mg v Part 1: Placebo |
| Number of subjects included in analysis | 148   |
| Analysis specification                  | Pre-specified                                 |
| Analysis type                           | superiority                                   |
| P-value                                 | = 1   |
| Method                                  | Wald Chi-Square                               |
| Parameter estimate                      | Odds ratio (OR)                               |
| Point estimate                          | 1   |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided                                       |
| lower limit                             | 0.42  |
| upper limit                             | 2.39  |

**Secondary: Odds of a more favorable response on WHO 11-point ordinal outcomes score on a scale on EOT (Day 5)**

|  |  |
|--|--|
| End point title  | Odds of a more favorable response on WHO 11-point ordinal outcomes score on a scale on EOT (Day 5) |
| End point description:   |  |
| The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented. All randomized participants in Part 1 who received $\geq 1$ dose of study drug and have data at the relevant time point are included. |  |
| End point type   | Secondary  |
| End point timeframe:   |  |
| EOT (Day 5)  |  |

| <b>End point values</b>     | Part 1:<br>Molnupiravir<br>200 mg | Part 1:<br>Molnupiravir<br>400 mg | Part 1:<br>Molnupiravir<br>800 mg | Part 1: Placebo |
|-----------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------|
| Subject group type          | Reporting group                   | Reporting group                   | Reporting group                   | Reporting group |
| Number of subjects analysed | 73                                | 73                                | 72                                | 75              |
| Units: participants         |                                   |                                   |                                   |                 |
| 0 (n=71,68,70,72)           | 2                                 | 0                                 | 1                                 | 0               |
| 1 (n=71,68,70,72)           | 2                                 | 1                                 | 1                                 | 2               |
| 2 (n=71,68,70,72)           | 3                                 | 5                                 | 0                                 | 9               |
| 3 (n=71,68,70,72)           | 0                                 | 2                                 | 2                                 | 1               |
| 4 (n=71,68,70,72)           | 29                                | 20                                | 27                                | 25              |

|                         |    |    |    |    |
|-------------------------|----|----|----|----|
| 5 (n=71,68,70,72)       | 27 | 31 | 28 | 26 |
| 6 (n=71,68,70,72)       | 7  | 8  | 8  | 8  |
| 7 (n=71,68,70,72)       | 0  | 0  | 0  | 0  |
| 8 (n=71,68,70,72)       | 1  | 1  | 1  | 0  |
| 9 (n=71,68,70,72)       | 0  | 0  | 2  | 1  |
| 10 (n=71,68,70,72)      | 0  | 0  | 0  | 0  |
| Missing (n=71,68,70,72) | 2  | 5  | 2  | 3  |

## Statistical analyses

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | WHO Day 5: Molnupiravir 200 mg vs. Placebo    |
| Comparison groups                       | Part 1: Molnupiravir 200 mg v Part 1: Placebo |
| Number of subjects included in analysis | 148   |
| Analysis specification                  | Pre-specified                                 |
| Analysis type                           | superiority                                   |
| P-value                                 | = 0.5022                                      |
| Method                                  | Wald Chi-Square                               |
| Parameter estimate                      | Odds ratio (OR)                               |
| Point estimate                          | 0.77  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided                                       |
| lower limit                             | 0.36  |
| upper limit                             | 1.64  |

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | WHO Day 5: Molnupiravir 800 mg vs. Placebo    |
| Comparison groups                       | Part 1: Molnupiravir 800 mg v Part 1: Placebo |
| Number of subjects included in analysis | 147   |
| Analysis specification                  | Pre-specified                                 |
| Analysis type                           | superiority                                   |
| P-value                                 | = 0.0991                                      |
| Method                                  | Wald Chi-Square                               |
| Parameter estimate                      | Odds ratio (OR)                               |
| Point estimate                          | 0.52  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided                                       |
| lower limit                             | 0.24  |
| upper limit                             | 1.13  |

|                                   |   |
|-----------------------------------|---|
| <b>Statistical analysis title</b> | WHO Day 5: Molnupiravir 400 mg vs. Placebo    |
| Comparison groups                 | Part 1: Molnupiravir 400 mg v Part 1: Placebo |

|   |                 |
|---|-----------------|
| Number of subjects included in analysis | 148             |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority     |
| P-value                                 | = 0.5204        |
| Method                                  | Wald Chi-Square |
| Parameter estimate                      | Odds ratio (OR) |
| Point estimate                          | 0.78            |
| Confidence interval                     |                 |
| level                                   | 95 %            |
| sides                                   | 2-sided         |
| lower limit                             | 0.37            |
| upper limit                             | 1.64            |

### Secondary: Odds of a more favorable response on WHO 11-point ordinal outcomes score on a scale on Day 10

|                 |   |
|-----------------|---|
| End point title | Odds of a more favorable response on WHO 11-point ordinal outcomes score on a scale on Day 10 |
|-----------------|---|

End point description:

The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented. All randomized participants in Part 1 who received  $\geq 1$  dose of study drug and have data at the relevant time point are included.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 10

| End point values            | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------|
| Subject group type          | Reporting group             | Reporting group             | Reporting group             | Reporting group |
| Number of subjects analysed | 73                          | 73                          | 72                          | 75              |
| Units: participants         |                             |                             |                             |                 |
| 0 (n=68,64,67,69)           | 3                           | 4                           | 2                           | 3               |
| 1 (n=68,64,67,69)           | 10                          | 7                           | 7                           | 7               |
| 2 (n=68,64,67,69)           | 26                          | 19                          | 22                          | 21              |
| 3 (n=68,64,67,69)           | 3                           | 4                           | 7                           | 8               |
| 4 (n=68,64,67,69)           | 8                           | 16                          | 7                           | 13              |
| 5 (n=68,64,67,69)           | 11                          | 9                           | 14                          | 11              |
| 6 (n=68,64,67,69)           | 4                           | 2                           | 5                           | 3               |
| 7 (n=68,64,67,69)           | 0                           | 0                           | 1                           | 0               |
| 8 (n=68,64,67,69)           | 2                           | 0                           | 0                           | 3               |
| 9 (n=68,64,67,69)           | 1                           | 0                           | 2                           | 0               |
| 10 (n=68,64,67,69)          | 0                           | 3                           | 0                           | 0               |
| Missing (n=68,64,67,69)     | 5                           | 9                           | 5                           | 6               |

## Statistical analyses

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | WHO Day 10: Molnupiravir 200 mg vs. Placebo   |
| Comparison groups                       | Part 1: Molnupiravir 200 mg v Part 1: Placebo |
| Number of subjects included in analysis | 148   |
| Analysis specification                  | Pre-specified                                 |
| Analysis type                           | superiority                                   |
| P-value                                 | = 0.6346                                      |
| Method                                  | Wald Chi-Square                               |
| Parameter estimate                      | Odds ratio (OR)                               |
| Point estimate                          | 1.18  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided                                       |
| lower limit                             | 0.6   |
| upper limit                             | 2.29  |

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | WHO Day 10: Molnupiravir 800 mg vs. Placebo   |
| Comparison groups                       | Part 1: Molnupiravir 800 mg v Part 1: Placebo |
| Number of subjects included in analysis | 147   |
| Analysis specification                  | Pre-specified                                 |
| Analysis type                           | superiority                                   |
| P-value                                 | = 0.8879                                      |
| Method                                  | Wald Chi-Square                               |
| Parameter estimate                      | Odds ratio (OR)                               |
| Point estimate                          | 0.95  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided                                       |
| lower limit                             | 0.49  |
| upper limit                             | 1.84  |

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | WHO Day 10: Molnupiravir 400 mg vs. Placebo   |
| Comparison groups                       | Part 1: Molnupiravir 400 mg v Part 1: Placebo |
| Number of subjects included in analysis | 148   |
| Analysis specification                  | Pre-specified                                 |
| Analysis type                           | superiority                                   |
| P-value                                 | = 0.7596                                      |
| Method                                  | Wald Chi-Square                               |
| Parameter estimate                      | Odds ratio (OR)                               |
| Point estimate                          | 0.9   |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided                                       |
| lower limit                             | 0.46  |
| upper limit                             | 1.75  |

## Secondary: Odds of a more favorable response on WHO 11-point ordinal outcomes score on a scale on Day 15

|  |   |
|--|---|
| End point title  | Odds of a more favorable response on WHO 11-point ordinal outcomes score on a scale on Day 15 |
| End point description:<br>The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented. All randomized participants in Part 1 who received $\geq 1$ dose of study drug and have data at the relevant time point are included. |   |
| End point type   | Secondary   |
| End point timeframe:<br>Day 15   |   |

| End point values            | Part 1: Molnupiravir 200 mg | Part 1: Molnupiravir 400 mg | Part 1: Molnupiravir 800 mg | Part 1: Placebo |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------|
| Subject group type          | Reporting group             | Reporting group             | Reporting group             | Reporting group |
| Number of subjects analysed | 73                          | 73                          | 72                          | 75              |
| Units: participants         |                             |                             |                             |                 |
| 0 (n=67,61,68,70)           | 10                          | 8                           | 10                          | 8               |
| 1 (n=67,61,68,70)           | 12                          | 12                          | 9                           | 11              |
| 2 (n=67,61,68,70)           | 25                          | 25                          | 27                          | 27              |
| 3 (n=67,61,68,70)           | 7                           | 5                           | 4                           | 8               |
| 4 (n=67,61,68,70)           | 4                           | 3                           | 3                           | 5               |
| 5 (n=67,61,68,70)           | 4                           | 4                           | 7                           | 4               |
| 6 (n=67,61,68,70)           | 2                           | 0                           | 0                           | 3               |
| 7 (n=67,61,68,70)           | 0                           | 0                           | 2                           | 1               |
| 8 (n=67,61,68,70)           | 3                           | 0                           | 1                           | 0               |
| 9 (n=67,61,68,70)           | 0                           | 1                           | 4                           | 2               |
| 10 (n=67,61,68,70)          | 0                           | 3                           | 1                           | 1               |
| Missing (n=67,61,68,70)     | 6                           | 12                          | 4                           | 5               |

## Statistical analyses

|   |   |
|---|---|
| Statistical analysis title              | WHO Day 15: Molnupiravir 200 mg vs. Placebo   |
| Comparison groups                       | Part 1: Molnupiravir 200 mg v Part 1: Placebo |
| Number of subjects included in analysis | 148   |
| Analysis specification                  | Pre-specified                                 |
| Analysis type                           | superiority                                   |
| P-value                                 | = 0.6002                                      |
| Method                                  | Wald Chi-Square                               |
| Parameter estimate                      | Odds ratio (OR)                               |
| Point estimate                          | 1.24  |

|                     |         |
|---------------------|---------|
| Confidence interval |         |
| level               | 95 %    |
| sides               | 2-sided |
| lower limit         | 0.55    |
| upper limit         | 2.82    |

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | WHO Day 15: Molnupiravir 800 mg vs. Placebo   |
| Comparison groups                       | Part 1: Molnupiravir 800 mg v Part 1: Placebo |
| Number of subjects included in analysis | 147   |
| Analysis specification                  | Pre-specified                                 |
| Analysis type                           | superiority                                   |
| P-value                                 | = 0.622                                       |
| Method                                  | Wald Chi-Square                               |
| Parameter estimate                      | Odds ratio (OR)                               |
| Point estimate                          | 0.82  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided                                       |
| lower limit                             | 0.38  |
| upper limit                             | 1.78  |

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | WHO Day 15: Molnupiravir 400 mg vs. Placebo   |
| Comparison groups                       | Part 1: Molnupiravir 400 mg v Part 1: Placebo |
| Number of subjects included in analysis | 148   |
| Analysis specification                  | Pre-specified                                 |
| Analysis type                           | superiority                                   |
| P-value                                 | = 0.4733                                      |
| Method                                  | Wald Chi-Square                               |
| Parameter estimate                      | Odds ratio (OR)                               |
| Point estimate                          | 1.37  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided                                       |
| lower limit                             | 0.58  |
| upper limit                             | 3.21  |

### **Secondary: Odds of a more favorable response on WHO 11-point ordinal outcomes score on a scale on Day 29**

|                 |   |
|-----------------|---|
| End point title | Odds of a more favorable response on WHO 11-point ordinal outcomes score on a scale on Day 29 |
|-----------------|---|

#### **End point description:**

The World Health Organization (WHO) outcome scale is an 11-point ordinal score that categorizes clinical progression. Score ranges from 0 ("uninfected") to 10 ("dead") with higher score indicating clinical progression. The number of participants at each score category is presented. All randomized participants in Part 1 who received  $\geq 1$  dose of study drug and have data at the relevant time point are

included.

|                      |           |
|----------------------|-----------|
| End point type       | Secondary |
| End point timeframe: |           |
| Day 29               |           |

| End point values            | Part 1:<br>Molnupiravir<br>200 mg | Part 1:<br>Molnupiravir<br>400 mg | Part 1:<br>Molnupiravir<br>800 mg | Part 1: Placebo |
|-----------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------|
| Subject group type          | Reporting group                   | Reporting group                   | Reporting group                   | Reporting group |
| Number of subjects analysed | 73                                | 73                                | 72                                | 75              |
| Units: participants         |                                   |                                   |                                   |                 |
| 0 (n=63,59,68,69)           | 25                                | 17                                | 29                                | 22              |
| 1 (n=63,59,68,69)           | 4                                 | 13                                | 7                                 | 9               |
| 2 (n=63,59,68,69)           | 24                                | 21                                | 17                                | 24              |
| 3 (n=63,59,68,69)           | 3                                 | 2                                 | 7                                 | 7               |
| 4 (n=63,59,68,69)           | 0                                 | 2                                 | 0                                 | 0               |
| 5 (n=63,59,68,69)           | 1                                 | 0                                 | 0                                 | 4               |
| 6 (n=63,59,68,69)           | 0                                 | 0                                 | 0                                 | 0               |
| 7 (n=63,59,68,69)           | 0                                 | 0                                 | 2                                 | 0               |
| 8 (n=63,59,68,69)           | 2                                 | 0                                 | 2                                 | 2               |
| 9 (n=63,59,68,69)           | 0                                 | 0                                 | 1                                 | 0               |
| 10 (n=63,59,68,69)          | 4                                 | 4                                 | 3                                 | 1               |
| Missing (n=63,59,68,69)     | 10                                | 14                                | 4                                 | 6               |

## Statistical analyses

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | WHO Day 29: Molnupiravir 200 mg vs. Placebo   |
| Comparison groups                       | Part 1: Molnupiravir 200 mg v Part 1: Placebo |
| Number of subjects included in analysis | 148   |
| Analysis specification                  | Pre-specified                                 |
| Analysis type                           |   |
| P-value                                 | = 0.7871                                      |
| Method                                  | Wald Chi-Square                               |
| Parameter estimate                      | Odds ratio (OR)                               |
| Point estimate                          | 0.86  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided                                       |
| lower limit                             | 0.28  |
| upper limit                             | 2.6   |

|                                   |   |
|-----------------------------------|---|
| <b>Statistical analysis title</b> | WHO Day 29: Molnupiravir 400 mg vs. Placebo   |
| Comparison groups                 | Part 1: Molnupiravir 400 mg v Part 1: Placebo |

|   |                 |
|---|-----------------|
| Number of subjects included in analysis | 148             |
| Analysis specification                  | Pre-specified   |
| Analysis type                           | superiority     |
| P-value                                 | = 0.9598        |
| Method                                  | Wald Chi-Square |
| Parameter estimate                      | Odds ratio (OR) |
| Point estimate                          | 0.97            |
| Confidence interval                     |                 |
| level                                   | 95 %            |
| sides                                   | 2-sided         |
| lower limit                             | 0.31            |
| upper limit                             | 3.06            |

|   |   |
|---|---|
| <b>Statistical analysis title</b>       | WHO Day 29: Molnupiravir 800 mg vs. Placebo   |
| Comparison groups                       | Part 1: Molnupiravir 800 mg v Part 1: Placebo |
| Number of subjects included in analysis | 147   |
| Analysis specification                  | Pre-specified                                 |
| Analysis type                           | superiority                                   |
| P-value                                 | = 0.667                                       |
| Method                                  | Wald Chi-Square                               |
| Parameter estimate                      | Odds ratio (OR)                               |
| Point estimate                          | 0.79  |
| Confidence interval                     |   |
| level                                   | 95 %  |
| sides                                   | 2-sided                                       |
| lower limit                             | 0.27  |
| upper limit                             | 2.31  |

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Up to 7 months

Adverse event reporting additional description:

All randomized participants are included in the all-cause mortality assessment; only confirmed (no imputed) deaths are reported.

All participants who received  $\geq 1$  dose of study treatment are included in the assessment of serious adverse events (SAEs) and nonserious AEs.

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 24.0 |
|--------------------|------|

### Reporting groups

|                       |                             |
|-----------------------|-----------------------------|
| Reporting group title | Part 1: Molnupiravir 200 mg |
|-----------------------|-----------------------------|

Reporting group description:

200 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)

|                       |                 |
|-----------------------|-----------------|
| Reporting group title | Part 1: Placebo |
|-----------------------|-----------------|

Reporting group description:

Placebo matching molnupiravir administered orally every 12 hours for 5 days (10 doses total)

|                       |                             |
|-----------------------|-----------------------------|
| Reporting group title | Part 1: Molnupiravir 800 mg |
|-----------------------|-----------------------------|

Reporting group description:

800 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)

|                       |                             |
|-----------------------|-----------------------------|
| Reporting group title | Part 1: Molnupiravir 400 mg |
|-----------------------|-----------------------------|

Reporting group description:

400 mg molnupiravir administered orally every 12 hours for 5 days (10 doses total)

| Serious adverse events  | Part 1: Molnupiravir 200 mg | Part 1: Placebo  | Part 1: Molnupiravir 800 mg |
|---|-----------------------------|------------------|-----------------------------|
| Total subjects affected by serious adverse events                   |                             |                  |                             |
| subjects affected / exposed   | 11 / 73 (15.07%)            | 12 / 75 (16.00%) | 13 / 72 (18.06%)            |
| number of deaths (all causes)                                       | 6                           | 2                | 7                           |
| number of deaths resulting from adverse events                      |                             |                  |                             |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                             |                  |                             |
| Clear cell renal cell carcinoma                                     |                             |                  |                             |
| subjects affected / exposed   | 0 / 73 (0.00%)              | 1 / 75 (1.33%)   | 0 / 72 (0.00%)              |
| occurrences causally related to treatment / all                     | 0 / 0                       | 0 / 1            | 0 / 0                       |
| deaths causally related to treatment / all                          | 0 / 0                       | 0 / 0            | 0 / 0                       |
| Vascular disorders  |                             |                  |                             |
| Deep vein thrombosis  |                             |                  |                             |

|  |                |                |                |
|--|----------------|----------------|----------------|
| subjects affected / exposed                          | 0 / 73 (0.00%) | 0 / 75 (0.00%) | 1 / 72 (1.39%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| Shock  |                |                |                |
| subjects affected / exposed                          | 0 / 73 (0.00%) | 0 / 75 (0.00%) | 0 / 72 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| Hypotension  |                |                |                |
| subjects affected / exposed                          | 1 / 73 (1.37%) | 0 / 75 (0.00%) | 0 / 72 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| General disorders and administration site conditions |                |                |                |
| Physical deconditioning                              |                |                |                |
| subjects affected / exposed                          | 0 / 73 (0.00%) | 0 / 75 (0.00%) | 1 / 72 (1.39%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| Respiratory, thoracic and mediastinal disorders      |                |                |                |
| Acute respiratory distress syndrome                  |                |                |                |
| subjects affected / exposed                          | 1 / 73 (1.37%) | 0 / 75 (0.00%) | 1 / 72 (1.39%) |
| occurrences causally related to treatment / all      | 0 / 1          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 1          |
| Acute respiratory failure                            |                |                |                |
| subjects affected / exposed                          | 3 / 73 (4.11%) | 2 / 75 (2.67%) | 2 / 72 (2.78%) |
| occurrences causally related to treatment / all      | 0 / 3          | 0 / 2          | 0 / 2          |
| deaths causally related to treatment / all           | 0 / 1          | 0 / 0          | 0 / 2          |
| Asthma   |                |                |                |
| subjects affected / exposed                          | 0 / 73 (0.00%) | 1 / 75 (1.33%) | 0 / 72 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |
| Pneumothorax spontaneous                             |                |                |                |
| subjects affected / exposed                          | 1 / 73 (1.37%) | 0 / 75 (0.00%) | 0 / 72 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all           | 0 / 0          | 0 / 0          | 0 / 0          |

|   |                |                |                |
|---|----------------|----------------|----------------|
| Pneumothorax                                    |                |                |                |
| subjects affected / exposed                     | 1 / 73 (1.37%) | 0 / 75 (0.00%) | 0 / 72 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Pulmonary oedema                                |                |                |                |
| subjects affected / exposed                     | 1 / 73 (1.37%) | 0 / 75 (0.00%) | 0 / 72 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Respiratory acidosis                            |                |                |                |
| subjects affected / exposed                     | 0 / 73 (0.00%) | 0 / 75 (0.00%) | 0 / 72 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Respiratory failure                             |                |                |                |
| subjects affected / exposed                     | 3 / 73 (4.11%) | 3 / 75 (4.00%) | 3 / 72 (4.17%) |
| occurrences causally related to treatment / all | 0 / 3          | 0 / 3          | 0 / 3          |
| deaths causally related to treatment / all      | 0 / 2          | 0 / 0          | 0 / 0          |
| Investigations                                  |                |                |                |
| Haemoglobin decreased                           |                |                |                |
| subjects affected / exposed                     | 1 / 73 (1.37%) | 0 / 75 (0.00%) | 0 / 72 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Transaminases increased                         |                |                |                |
| subjects affected / exposed                     | 0 / 73 (0.00%) | 0 / 75 (0.00%) | 1 / 72 (1.39%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Cardiac disorders                               |                |                |                |
| Cardiac arrest                                  |                |                |                |
| subjects affected / exposed                     | 0 / 73 (0.00%) | 0 / 75 (0.00%) | 0 / 72 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Supraventricular tachycardia                    |                |                |                |
| subjects affected / exposed                     | 0 / 73 (0.00%) | 1 / 75 (1.33%) | 0 / 72 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

|   |                |                |                |
|---|----------------|----------------|----------------|
| Blood and lymphatic system disorders            |                |                |                |
| Anaemia   |                |                |                |
| subjects affected / exposed                     | 0 / 73 (0.00%) | 0 / 75 (0.00%) | 0 / 72 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Gastrointestinal disorders                      |                |                |                |
| Haemorrhoids                                    |                |                |                |
| subjects affected / exposed                     | 1 / 73 (1.37%) | 0 / 75 (0.00%) | 0 / 72 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Hepatobiliary disorders                         |                |                |                |
| Cholestasis                                     |                |                |                |
| subjects affected / exposed                     | 0 / 73 (0.00%) | 0 / 75 (0.00%) | 1 / 72 (1.39%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Skin and subcutaneous tissue disorders          |                |                |                |
| Skin ulcer                                      |                |                |                |
| subjects affected / exposed                     | 0 / 73 (0.00%) | 1 / 75 (1.33%) | 0 / 72 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Urticaria                                       |                |                |                |
| subjects affected / exposed                     | 1 / 73 (1.37%) | 0 / 75 (0.00%) | 0 / 72 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Renal and urinary disorders                     |                |                |                |
| Chronic kidney disease                          |                |                |                |
| subjects affected / exposed                     | 0 / 73 (0.00%) | 0 / 75 (0.00%) | 1 / 72 (1.39%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Acute kidney injury                             |                |                |                |
| subjects affected / exposed                     | 1 / 73 (1.37%) | 0 / 75 (0.00%) | 1 / 72 (1.39%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Musculoskeletal and connective tissue disorders |                |                |                |
| Gouty arthritis                                 |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 73 (0.00%) | 0 / 75 (0.00%) | 0 / 72 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| <b>Infections and infestations</b>              |                |                |                |
| <b>Bacteraemia</b>                              |                |                |                |
| subjects affected / exposed                     | 2 / 73 (2.74%) | 0 / 75 (0.00%) | 0 / 72 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 1          | 0 / 0          | 0 / 0          |
| <b>COVID-19</b>                                 |                |                |                |
| subjects affected / exposed                     | 7 / 73 (9.59%) | 6 / 75 (8.00%) | 5 / 72 (6.94%) |
| occurrences causally related to treatment / all | 0 / 7          | 0 / 6          | 0 / 5          |
| deaths causally related to treatment / all      | 0 / 4          | 0 / 0          | 0 / 2          |
| <b>COVID-19 pneumonia</b>                       |                |                |                |
| subjects affected / exposed                     | 0 / 73 (0.00%) | 5 / 75 (6.67%) | 3 / 72 (4.17%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 5          | 0 / 3          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 1          | 0 / 1          |
| <b>Peritonitis bacterial</b>                    |                |                |                |
| subjects affected / exposed                     | 1 / 73 (1.37%) | 0 / 75 (0.00%) | 0 / 72 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| <b>Pneumonia</b>                                |                |                |                |
| subjects affected / exposed                     | 0 / 73 (0.00%) | 0 / 75 (0.00%) | 2 / 72 (2.78%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 2          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| <b>Pulmonary sepsis</b>                         |                |                |                |
| subjects affected / exposed                     | 0 / 73 (0.00%) | 1 / 75 (1.33%) | 0 / 72 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 1          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 1          | 0 / 0          |
| <b>Septic shock</b>                             |                |                |                |
| subjects affected / exposed                     | 0 / 73 (0.00%) | 0 / 75 (0.00%) | 1 / 72 (1.39%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| <b>Urinary tract infection enterococcal</b>     |                |                |                |

|   |                |                |                |
|---|----------------|----------------|----------------|
| subjects affected / exposed                     | 0 / 73 (0.00%) | 0 / 75 (0.00%) | 1 / 72 (1.39%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Pneumonia bacterial                             |                |                |                |
| subjects affected / exposed                     | 1 / 73 (1.37%) | 0 / 75 (0.00%) | 2 / 72 (2.78%) |
| occurrences causally related to treatment / all | 0 / 1          | 0 / 0          | 0 / 2          |
| deaths causally related to treatment / all      | 0 / 1          | 0 / 0          | 0 / 0          |
| Metabolism and nutrition disorders              |                |                |                |
| Hyponatraemia                                   |                |                |                |
| subjects affected / exposed                     | 0 / 73 (0.00%) | 0 / 75 (0.00%) | 1 / 72 (1.39%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 1          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Lactic acidosis                                 |                |                |                |
| subjects affected / exposed                     | 0 / 73 (0.00%) | 0 / 75 (0.00%) | 0 / 72 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |
| Metabolic acidosis                              |                |                |                |
| subjects affected / exposed                     | 0 / 73 (0.00%) | 0 / 75 (0.00%) | 0 / 72 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0          | 0 / 0          | 0 / 0          |
| deaths causally related to treatment / all      | 0 / 0          | 0 / 0          | 0 / 0          |

|   |                                |  |  |
|---|--------------------------------|--|--|
| <b>Serious adverse events</b>                                       | Part 1: Molnupiravir<br>400 mg |  |  |
| Total subjects affected by serious adverse events                   |                                |  |  |
| subjects affected / exposed   | 9 / 73 (12.33%)                |  |  |
| number of deaths (all causes)                                       | 4                              |  |  |
| number of deaths resulting from adverse events                      |                                |  |  |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                                |  |  |
| Clear cell renal cell carcinoma                                     |                                |  |  |
| subjects affected / exposed   | 0 / 73 (0.00%)                 |  |  |
| occurrences causally related to treatment / all                     | 0 / 0                          |  |  |
| deaths causally related to treatment / all                          | 0 / 0                          |  |  |
| Vascular disorders  |                                |  |  |
| Deep vein thrombosis  |                                |  |  |

|  |                |  |  |
|--|----------------|--|--|
| subjects affected / exposed                          | 0 / 73 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Shock  |                |  |  |
| subjects affected / exposed                          | 1 / 73 (1.37%) |  |  |
| occurrences causally related to treatment / all      | 0 / 1          |  |  |
| deaths causally related to treatment / all           | 0 / 1          |  |  |
| Hypotension  |                |  |  |
| subjects affected / exposed                          | 0 / 73 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| General disorders and administration site conditions |                |  |  |
| Physical deconditioning                              |                |  |  |
| subjects affected / exposed                          | 0 / 73 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Respiratory, thoracic and mediastinal disorders      |                |  |  |
| Acute respiratory distress syndrome                  |                |  |  |
| subjects affected / exposed                          | 1 / 73 (1.37%) |  |  |
| occurrences causally related to treatment / all      | 0 / 1          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Acute respiratory failure                            |                |  |  |
| subjects affected / exposed                          | 0 / 73 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Asthma   |                |  |  |
| subjects affected / exposed                          | 0 / 73 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |
| Pneumothorax spontaneous                             |                |  |  |
| subjects affected / exposed                          | 0 / 73 (0.00%) |  |  |
| occurrences causally related to treatment / all      | 0 / 0          |  |  |
| deaths causally related to treatment / all           | 0 / 0          |  |  |

|   |                |  |  |
|---|----------------|--|--|
| Pneumothorax                                    |                |  |  |
| subjects affected / exposed                     | 0 / 73 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Pulmonary oedema                                |                |  |  |
| subjects affected / exposed                     | 0 / 73 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Respiratory acidosis                            |                |  |  |
| subjects affected / exposed                     | 1 / 73 (1.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Respiratory failure                             |                |  |  |
| subjects affected / exposed                     | 4 / 73 (5.48%) |  |  |
| occurrences causally related to treatment / all | 0 / 4          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Investigations                                  |                |  |  |
| Haemoglobin decreased                           |                |  |  |
| subjects affected / exposed                     | 0 / 73 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Transaminases increased                         |                |  |  |
| subjects affected / exposed                     | 1 / 73 (1.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Cardiac disorders                               |                |  |  |
| Cardiac arrest                                  |                |  |  |
| subjects affected / exposed                     | 1 / 73 (1.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 1          |  |  |
| Supraventricular tachycardia                    |                |  |  |
| subjects affected / exposed                     | 0 / 73 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |

|   |                |  |  |
|---|----------------|--|--|
| Blood and lymphatic system disorders            |                |  |  |
| Anaemia   |                |  |  |
| subjects affected / exposed                     | 1 / 73 (1.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Gastrointestinal disorders                      |                |  |  |
| Haemorrhoids                                    |                |  |  |
| subjects affected / exposed                     | 0 / 73 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Hepatobiliary disorders                         |                |  |  |
| Cholestasis                                     |                |  |  |
| subjects affected / exposed                     | 0 / 73 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Skin and subcutaneous tissue disorders          |                |  |  |
| Skin ulcer                                      |                |  |  |
| subjects affected / exposed                     | 0 / 73 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Urticaria                                       |                |  |  |
| subjects affected / exposed                     | 0 / 73 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Renal and urinary disorders                     |                |  |  |
| Chronic kidney disease                          |                |  |  |
| subjects affected / exposed                     | 0 / 73 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Acute kidney injury                             |                |  |  |
| subjects affected / exposed                     | 0 / 73 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Musculoskeletal and connective tissue disorders |                |  |  |
| Gouty arthritis                                 |                |  |  |

|   |                |  |  |
|---|----------------|--|--|
| subjects affected / exposed                     | 1 / 73 (1.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Infections and infestations                     |                |  |  |
| Bacteraemia                                     |                |  |  |
| subjects affected / exposed                     | 0 / 73 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| COVID-19  |                |  |  |
| subjects affected / exposed                     | 4 / 73 (5.48%) |  |  |
| occurrences causally related to treatment / all | 0 / 4          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| COVID-19 pneumonia                              |                |  |  |
| subjects affected / exposed                     | 1 / 73 (1.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 1          |  |  |
| Peritonitis bacterial                           |                |  |  |
| subjects affected / exposed                     | 0 / 73 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Pneumonia                                       |                |  |  |
| subjects affected / exposed                     | 1 / 73 (1.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Pulmonary sepsis                                |                |  |  |
| subjects affected / exposed                     | 0 / 73 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Septic shock                                    |                |  |  |
| subjects affected / exposed                     | 1 / 73 (1.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 1          |  |  |
| Urinary tract infection enterococcal            |                |  |  |

|   |                |  |  |
|---|----------------|--|--|
| subjects affected / exposed                     | 0 / 73 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Pneumonia bacterial                             |                |  |  |
| subjects affected / exposed                     | 0 / 73 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Metabolism and nutrition disorders              |                |  |  |
| Hyponatraemia                                   |                |  |  |
| subjects affected / exposed                     | 0 / 73 (0.00%) |  |  |
| occurrences causally related to treatment / all | 0 / 0          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Lactic acidosis                                 |                |  |  |
| subjects affected / exposed                     | 1 / 73 (1.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |
| Metabolic acidosis                              |                |  |  |
| subjects affected / exposed                     | 1 / 73 (1.37%) |  |  |
| occurrences causally related to treatment / all | 0 / 1          |  |  |
| deaths causally related to treatment / all      | 0 / 0          |  |  |

Frequency threshold for reporting non-serious adverse events: 5 %

| <b>Non-serious adverse events</b>                     | Part 1: Molnupiravir<br>200 mg | Part 1: Placebo  | Part 1: Molnupiravir<br>800 mg |
|---|--------------------------------|------------------|--------------------------------|
| Total subjects affected by non-serious adverse events |                                |                  |                                |
| subjects affected / exposed                           | 11 / 73 (15.07%)               | 13 / 75 (17.33%) | 7 / 72 (9.72%)                 |
| Investigations  |                                |                  |                                |
| Aspartate aminotransferase increased                  |                                |                  |                                |
| subjects affected / exposed                           | 3 / 73 (4.11%)                 | 3 / 75 (4.00%)   | 5 / 72 (6.94%)                 |
| occurrences (all)                                     | 3                              | 3                | 6                              |
| Alanine aminotransferase increased                    |                                |                  |                                |
| subjects affected / exposed                           | 4 / 73 (5.48%)                 | 8 / 75 (10.67%)  | 7 / 72 (9.72%)                 |
| occurrences (all)                                     | 4                              | 8                | 7                              |
| Gastrointestinal disorders                            |                                |                  |                                |

|  |                     |                     |                     |
|--|---------------------|---------------------|---------------------|
| Constipation<br>subjects affected / exposed<br>occurrences (all)   | 5 / 73 (6.85%)<br>5 | 5 / 75 (6.67%)<br>5 | 0 / 72 (0.00%)<br>0 |
| Metabolism and nutrition disorders<br>Hyperglycaemia<br>subjects affected / exposed<br>occurrences (all) | 4 / 73 (5.48%)<br>4 | 1 / 75 (1.33%)<br>1 | 0 / 72 (0.00%)<br>0 |

|   |                                |  |  |
|---|--------------------------------|--|--|
| <b>Non-serious adverse events</b>   | Part 1: Molnupiravir<br>400 mg |  |  |
| Total subjects affected by non-serious<br>adverse events<br>subjects affected / exposed                       | 11 / 73 (15.07%)               |  |  |
| Investigations<br>Aspartate aminotransferase<br>increased<br>subjects affected / exposed<br>occurrences (all) | 5 / 73 (6.85%)<br>5            |  |  |
| Alanine aminotransferase increased<br>subjects affected / exposed<br>occurrences (all)                        | 5 / 73 (6.85%)<br>5            |  |  |
| Gastrointestinal disorders<br>Constipation<br>subjects affected / exposed<br>occurrences (all)                | 2 / 73 (2.74%)<br>2            |  |  |
| Metabolism and nutrition disorders<br>Hyperglycaemia<br>subjects affected / exposed<br>occurrences (all)      | 5 / 73 (6.85%)<br>5            |  |  |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date             | Amendment   |
|------------------|---|
| 17 December 2020 | AM1: To revise the dose selection process before initiation of Part 2 (Phase 3), update the benefit/risk assessment, clarify the primary efficacy endpoint definition, and add a new inclusion criterion and discontinuation criterion. |

Notes:

---

### Interruptions (globally)

Were there any global interruptions to the trial? Yes

| Date           | Interruption  | Restart date |
|----------------|---|--------------|
| 11 August 2021 | This study was terminated early for business reasons. | -            |

Notes:

### Limitations and caveats

None reported